Tau Therapeutics Closes $3M Private Equity Financing

Tau Therapeutics LLC, a Charlottesville, VA-based oncology company, has closed a $3m private equity financing.

Backers were not disclosed.

Led by President and CEO Andrew Krouse, Tau develops T-type calcium channel inhibitors for the treatment of solid tumors.

The company intends to use the proceeds for Phase 1b clinical trial for its first product candidate mibefradil, which is currently being conducted with the National Cancer Institute’s Adult Brain Tumor Consortium, as well as for development of new therapies and diagnostics in multiple indications.
Tau plans to present results of the Phase Ib trial in 2013.

The company has raised over $10m from private investors throughout the United States and received over $12m in non-dilutive resources in the last six years.



Join the discussion